Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
Add more filters










Publication year range
1.
Science ; 373(6562): eabg5673, 2021 Sep 24.
Article in English | MEDLINE | ID: mdl-34554772

ABSTRACT

Wang et al. (Research Articles, 11 December 2020, p. 1295) reported a large decrease in CO2 fertilization effect (CFE) across the globe during the period 1982­2015 and suggested that ecosystem models underestimate the rate of CFE decline. We find that their claims are artifacts of incorrect processing of satellite data and problematic methods for deriving and comparing CFE between satellite data and model simulations.


Subject(s)
Carbon Dioxide , Photosynthesis , Fertilization
2.
Proc Natl Acad Sci U S A ; 118(10)2021 03 09.
Article in English | MEDLINE | ID: mdl-33649218

ABSTRACT

Locally adapted temperate tree populations exhibit genetic trade-offs among climate-related traits that can be exacerbated by selective breeding and are challenging to manage under climate change. To inform climatically adaptive forest management, we investigated the genetic architecture and impacts of selective breeding on four climate-related traits in 105 natural and 20 selectively bred lodgepole pine populations from western Canada. Growth, cold injury, growth initiation, and growth cessation phenotypes were tested for associations with 18,600 single-nucleotide polymorphisms (SNPs) in natural populations to identify "positive effect alleles" (PEAs). The effects of artificial selection for faster growth on the frequency of PEAs associated with each trait were quantified in breeding populations from different climates. Substantial shifts in PEA proportions and frequencies were observed across many loci after two generations of selective breeding for height, and responses of phenology-associated PEAs differed strongly among climatic regions. Extensive genetic overlap was evident among traits. Alleles most strongly associated with greater height were often associated with greater cold injury and delayed phenology, although it is unclear whether potential trade-offs arose directly from pleiotropy or indirectly via genetic linkage. Modest variation in multilocus PEA frequencies among populations was associated with large phenotypic differences and strong climatic gradients, providing support for assisted gene flow polices. Relationships among genotypes, phenotypes, and climate in natural populations were maintained or strengthened by selective breeding. However, future adaptive phenotypes and assisted gene flow may be compromised if selective breeding further increases the PEA frequencies of SNPs involved in adaptive trade-offs among climate-related traits.


Subject(s)
Adaptation, Physiological , Climate Change , Genome, Plant , Plant Breeding , Quantitative Trait Loci , Tracheophyta/genetics , Pinus/genetics , Pinus/growth & development , Selective Breeding , Tracheophyta/growth & development
3.
Evol Appl ; 13(1): 116-131, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31892947

ABSTRACT

We evaluate genomic data, relative to phenotypic and climatic data, as a basis for assisted gene flow and genetic conservation. Using a seedling common garden trial of 281 lodgepole pine (Pinus contorta) populations from across western Canada, we compare genomic data to phenotypic and climatic data to assess their effectiveness in characterizing the climatic drivers and spatial scale of local adaptation in this species. We find that phenotype-associated loci are equivalent or slightly superior to climate data for describing local adaptation in seedling traits, but that climate data are superior to genomic data that have not been selected for phenotypic associations. We also find agreement between the climate variables associated with genomic variation and with 20-year heights from a long-term provenance trial, suggesting that genomic data may be a viable option for identifying climatic drivers of local adaptation where phenotypic data are unavailable. Genetic clines associated with the experimental traits occur at broad spatial scales, suggesting that standing variation of adaptive alleles for this and similar species does not require management at scales finer than those indicated by phenotypic data. This study demonstrates that genomic data are most useful when paired with phenotypic data, but can also fill some of the traditional roles of phenotypic data in management of species for which phenotypic trials are not feasible.

4.
Evol Appl ; 11(2): 166-181, 2018 02.
Article in English | MEDLINE | ID: mdl-29387153

ABSTRACT

Hybrid zones contain extensive standing genetic variation that facilitates rapid responses to selection. The Picea glauca × Picea engelmannii hybrid zone in western Canada is the focus of tree breeding programs that annually produce ~90 million reforestation seedlings. Understanding the direct and indirect effects of selective breeding on adaptive variation is necessary to implement assisted gene flow (AGF) polices in Alberta and British Columbia that match these seedlings with future climates. We decomposed relationships among hybrid ancestry, adaptive traits, and climate to understand the implications of selective breeding for climate adaptations and AGF strategies. The effects of selection on associations among hybrid index estimated from ~6,500 SNPs, adaptive traits, and provenance climates were assessed for ~2,400 common garden seedlings. Hybrid index differences between natural and selected seedlings within breeding zones were small in Alberta (average +2%), but larger and more variable in BC (average -7%, range -24% to +1%), slightly favoring P. glauca ancestry. The average height growth gain of selected seedlings over natural seedlings within breeding zones was 36% (range 12%-86%). Clines in growth with temperature-related variables were strong, but differed little between selected and natural populations. Seedling hybrid index and growth trait associations with evapotranspiration-related climate variables were stronger in selected than in natural seedlings, indicating possible preadaptation to drier future climates. Associations among cold hardiness, hybrid ancestry, and cold-related climate variables dominated signals of local adaptation and were preserved in breeding populations. Strong hybrid ancestry-phenotype-climate associations suggest that AGF will be necessary to match interior spruce breeding populations with shifting future climates. The absence of antagonistic selection responses among traits and maintenance of cold adaptation in selected seedlings suggests breeding populations can be safely redeployed using AGF prescriptions similar to those of natural populations.

5.
J Clin Invest ; 127(12): 4437-4448, 2017 12 01.
Article in English | MEDLINE | ID: mdl-29106386

ABSTRACT

Ebolaviruses and marburgviruses belong to the family Filoviridae and cause high lethality in infected patients. There are currently no licensed filovirus vaccines or antiviral therapies. The development of broad-spectrum therapies against members of the Marburgvirus genus, including Marburg virus (MARV) and Ravn virus (RAVV), is difficult because of substantial sequence variability. RNAi therapeutics offer a potential solution, as identification of conserved target nucleotide sequences may confer activity across marburgvirus variants. Here, we assessed the therapeutic efficacy of lipid nanoparticle (LNP) delivery of a single nucleoprotein-targeting (NP-targeting) siRNA in nonhuman primates at advanced stages of MARV or RAVV disease to mimic cases in which patients begin treatment for fulminant disease. Sixteen rhesus monkeys were lethally infected with MARV or RAVV and treated with NP siRNA-LNP, with MARV-infected animals beginning treatment four or five days after infection and RAVV-infected animals starting treatment three or six days after infection. While all untreated animals succumbed to disease, NP siRNA-LNP treatment conferred 100% survival of RAVV-infected macaques, even when treatment began just 1 day prior to the death of the control animals. In MARV-infected animals, day-4 treatment initiation resulted in 100% survival, and day-5 treatment resulted in 50% survival. These results identify a single siRNA therapeutic that provides broad-spectrum protection against both MARV and RAVV.


Subject(s)
Drug Delivery Systems/methods , Marburg Virus Disease/drug therapy , Marburgvirus , Nanoparticles/therapeutic use , RNA, Small Interfering/pharmacology , Animals , Macaca mulatta , Marburg Virus Disease/metabolism , Marburg Virus Disease/pathology , Nanoparticles/chemistry , RNA, Small Interfering/chemistry
6.
Nat Microbiol ; 1(10): 16142, 2016 08 22.
Article in English | MEDLINE | ID: mdl-27670117

ABSTRACT

Although significant progress has been made in developing therapeutics against Zaire ebolavirus, these therapies do not protect against other Ebola species such as Sudan ebolavirus (SUDV). Here, we describe an RNA interference therapeutic comprising siRNA targeting the SUDV VP35 gene encapsulated in lipid nanoparticle (LNP) technology with increased potency beyond formulations used in TKM-Ebola clinical trials. Twenty-five rhesus monkeys were challenged with a lethal dose of SUDV. Twenty animals received siRNA-LNP beginning at 1, 2, 3, 4 or 5 days post-challenge. VP35-targeting siRNA-LNP treatment resulted in up to 100% survival, even when initiated when fever, viraemia and disease signs were evident. Treatment effectively controlled viral replication, mediating up to 4 log10 reductions after dosing. Mirroring clinical findings, a correlation between high viral loads and fatal outcome was observed, emphasizing the importance of stratifying efficacy according to viral load. In summary, strong survival benefit and rapid control of SUDV replication by VP35-targeting LNP confirm its therapeutic potential in combatting this lethal disease.


Subject(s)
Hemorrhagic Fever, Ebola/therapy , Lipids , RNA Interference , RNA, Small Interfering/therapeutic use , Animals , Antibodies, Viral , Disease Models, Animal , Drug Compounding , Ebolavirus/isolation & purification , Ebolavirus/pathogenicity , Hemorrhagic Fever, Ebola/virology , Hep G2 Cells , Humans , Macaca mulatta , Nanoparticles/administration & dosage , Nanoparticles/chemistry , RNA, Small Interfering/genetics , Sudan , Viral Load/drug effects , Viral Regulatory and Accessory Proteins/genetics , Viral Regulatory and Accessory Proteins/metabolism , Viremia/therapy , Virus Replication
7.
Nature ; 521(7552): 362-5, 2015 May 21.
Article in English | MEDLINE | ID: mdl-25901685

ABSTRACT

The current outbreak of Ebola virus in West Africa is unprecedented, causing more cases and fatalities than all previous outbreaks combined, and has yet to be controlled. Several post-exposure interventions have been employed under compassionate use to treat patients repatriated to Europe and the United States. However, the in vivo efficacy of these interventions against the new outbreak strain of Ebola virus is unknown. Here we show that lipid-nanoparticle-encapsulated short interfering RNAs (siRNAs) rapidly adapted to target the Makona outbreak strain of Ebola virus are able to protect 100% of rhesus monkeys against lethal challenge when treatment was initiated at 3 days after exposure while animals were viraemic and clinically ill. Although all infected animals showed evidence of advanced disease including abnormal haematology, blood chemistry and coagulopathy, siRNA-treated animals had milder clinical features and fully recovered, while the untreated control animals succumbed to the disease. These results represent the first, to our knowledge, successful demonstration of therapeutic anti-Ebola virus efficacy against the new outbreak strain in nonhuman primates and highlight the rapid development of lipid-nanoparticle-delivered siRNA as a countermeasure against this highly lethal human disease.


Subject(s)
Ebolavirus/drug effects , Ebolavirus/genetics , Hemorrhagic Fever, Ebola/therapy , Hemorrhagic Fever, Ebola/virology , Nanoparticles/administration & dosage , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/therapeutic use , Animals , Base Sequence , Disease Models, Animal , Ebolavirus/classification , Female , Hemorrhagic Fever, Ebola/pathology , Hemorrhagic Fever, Ebola/prevention & control , Humans , Macaca mulatta/virology , Male , RNA, Small Interfering/pharmacology , Survival Analysis , Time Factors , Treatment Outcome , Viral Load/drug effects
8.
Sci Transl Med ; 6(250): 250ra116, 2014 Aug 20.
Article in English | MEDLINE | ID: mdl-25143366

ABSTRACT

Marburg virus (MARV) and the closely related filovirus Ebola virus cause severe and often fatal hemorrhagic fever (HF) in humans and nonhuman primates with mortality rates up to 90%. There are no vaccines or drugs approved for human use, and no postexposure treatment has completely protected nonhuman primates against MARV-Angola, the strain associated with the highest rate of mortality in naturally occurring human outbreaks. Studies performed with other MARV strains assessed candidate treatments at times shortly after virus exposure, before signs of disease are detectable. We assessed the efficacy of lipid nanoparticle (LNP) delivery of anti-MARV nucleoprotein (NP)-targeting small interfering RNA (siRNA) at several time points after virus exposure, including after the onset of detectable disease in a uniformly lethal nonhuman primate model of MARV-Angola HF. Twenty-one rhesus monkeys were challenged with a lethal dose of MARV-Angola. Sixteen of these animals were treated with LNP containing anti-MARV NP siRNA beginning at 30 to 45 min, 1 day, 2 days, or 3 days after virus challenge. All 16 macaques that received LNP-encapsulated anti-MARV NP siRNA survived infection, whereas the untreated or mock-treated control subjects succumbed to disease between days 7 and 9 after infection. These results represent the successful demonstration of therapeutic anti-MARV-Angola efficacy in nonhuman primates and highlight the substantial impact of an LNP-delivered siRNA therapeutic as a countermeasure against this highly lethal human disease.


Subject(s)
Lipids/therapeutic use , Macaca mulatta/virology , Marburg Virus Disease/virology , Marburgvirus/physiology , Nanoparticles/therapeutic use , RNA, Small Interfering/therapeutic use , Animals , Antigens, Viral/immunology , Humans , Macaca mulatta/immunology , Marburg Virus Disease/pathology , Marburg Virus Disease/therapy , Marburgvirus/immunology , Nanoparticles/chemistry , RNA, Viral/metabolism , Survival Analysis , Treatment Outcome , Viremia/pathology
9.
Cancer Res ; 74(17): 4752-61, 2014 Sep 01.
Article in English | MEDLINE | ID: mdl-24958469

ABSTRACT

Histone deacetylase 2 (HDAC2) is a chromatin modifier involved in epigenetic regulation of cell cycle, apoptosis, and differentiation that is upregulated commonly in human hepatocellular carcinoma (HCC). In this study, we show that specific targeting of this HDAC isoform is sufficient to inhibit HCC progression. siRNA-mediated silencing of HDAC inhibited HCC cell growth by blocking cell-cycle progression and inducing apoptosis. These effects were associated with deregulation of HDAC-regulated genes that control cell cycle, apoptosis, and lipid metabolism, specifically, by upregulation of p27 and acetylated p53 and by downregulation of CDK6 and BCL2. We found that HDAC2 silencing in HCC cells also strongly inhibited PPARγ signaling and other regulators of glycolysis (ChREBPα and GLUT4) and lipogenesis (SREBP1C and FAS), eliciting a marked decrease in fat accumulation. Notably, systemic delivery of HDAC2 siRNA encapsulated in lipid nanoparticles was sufficient to blunt the growth of human HCC in a murine xenograft model. Our findings offer preclinical proof-of-concept for HDAC2 blockade as a systemic therapy for liver cancer.


Subject(s)
Carcinoma, Hepatocellular/genetics , Histone Deacetylase 2/genetics , Liver Neoplasms/genetics , Protein Isoforms/genetics , Animals , Apoptosis/genetics , Carcinoma, Hepatocellular/pathology , Cell Cycle/genetics , Cell Line, Tumor , Cyclin-Dependent Kinase 6/genetics , Disease Progression , Down-Regulation/genetics , Gene Expression Regulation, Neoplastic/genetics , Glycolysis/genetics , Hep G2 Cells , Humans , Lipid Metabolism/genetics , Lipogenesis/genetics , Liver Neoplasms/pathology , Male , Mice , Mice, SCID , PPAR gamma/genetics , Proliferating Cell Nuclear Antigen/genetics , Signal Transduction/genetics , Tumor Suppressor Protein p53/genetics , Up-Regulation/genetics , bcl-2-Associated X Protein/genetics
10.
J Virol ; 88(9): 4647-56, 2014 May.
Article in English | MEDLINE | ID: mdl-24478422

ABSTRACT

UNLABELLED: We have recently shown that a cocktail of two short synthetic hairpin RNAs (sshRNAs), targeting the internal ribosome entry site of hepatitis C virus (HCV) formulated with lipid nanoparticles, was able to suppress viral replication in chimeric mice infected with HCV GT1a by up to 2.5 log10 (H. Ma et al., Gastroenterology 146:63-66.e5, http://dx.doi.org/10.1053/j.gastro.2013.09.049) Viral load remained about 1 log10 below pretreatment levels 21 days after the end of dosing. We have now sequenced the HCV viral RNA amplified from serum of treated mice after the 21-day follow-up period. Viral RNA from the HCV sshRNA-treated groups was altered in sequences complementary to the sshRNAs and nowhere else in the 500-nucleotide sequenced region, while the viruses from the control group that received an irrelevant sshRNA had no mutations in that region. The ability of the most commonly selected mutations to confer resistance to the sshRNAs was confirmed in vitro by introducing those mutations into HCV-luciferase reporters. The mutations most frequently selected by sshRNA treatment within the sshRNA target sequence occurred at the most polymorphic residues, as identified from an analysis of available clinical isolates. These results demonstrate a direct antiviral activity with effective HCV suppression, demonstrate the added selective pressure of combination therapy, and confirm an RNA interference (RNAi) mechanism of action. IMPORTANCE: This study presents a detailed analysis of the impact of treating a hepatitis C virus (HCV)-infected animal with synthetic hairpin-shaped RNAs that can degrade the virus's RNA genome. These RNAs can reduce the viral load in these animals by over 99% after 1 to 2 injections. The study results confirm that the viral rebound that often occurred a few weeks after treatment is due to emergence of a virus whose genome is mutated in the sequences targeted by the RNAs. The use of two RNA inhibitors, which is more effective than use of either one by itself, requires that any resistant virus have mutations in the targets sites of both agents, a higher hurdle, if the virus is to retain the ability to replicate efficiently. These results demonstrate a direct antiviral activity with effective HCV suppression, demonstrate the added selective pressure of combination therapy, and confirm an RNAi mechanism of action.


Subject(s)
Antiviral Agents/metabolism , Hepacivirus/drug effects , RNA, Small Interfering/metabolism , Selection, Genetic , Animals , Disease Models, Animal , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis C/drug therapy , Hepatitis C/virology , Male , Mice , Mutation , RNA, Small Interfering/genetics , Sequence Analysis
11.
Gastroenterology ; 146(1): 63-6.e5, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24076507

ABSTRACT

Short synthetic hairpin RNAs (sshRNAs) (SG220 and SG273) that target the internal ribosome entry site of the hepatitis C virus (HCV) were formulated into lipid nanoparticles and administered intravenously to HCV-infected urokinase plasminogen activator-severe combined immunodeficient mice with livers repopulated with human hepatocytes (humanized livers). Weekly administration of 2.5 mg/kg of each sshRNA for 2 weeks resulted in a maximal mean reduction in viral load of 2.5 log10 from baseline. The viral load remained reduced by more than 90% at 14 days after the last dose was given. The sshRNAs were well tolerated and did not significantly increase liver enzyme levels. These findings indicate the in vivo efficacy of a synthetic RNA inhibitor against the HCV genome in reducing HCV infection.


Subject(s)
Antiviral Agents/pharmacology , Hepacivirus/drug effects , Hepatocytes/drug effects , Liver/drug effects , RNA, Small Interfering/pharmacology , Viral Load/drug effects , Animals , Chimera , Disease Models, Animal , Humans , Mice , Mice, SCID , Nanoparticles
12.
J Infect Dis ; 209(4): 562-70, 2014 Feb 15.
Article in English | MEDLINE | ID: mdl-23990568

ABSTRACT

BACKGROUND: Marburg virus (MARV) infection causes severe morbidity and mortality in humans and nonhuman primates. Currently, there are no licensed therapeutics available for treating MARV infection. Here, we present the in vitro development and in vivo evaluation of lipid-encapsulated small interfering RNA (siRNA) as a potential therapeutic for the treatment of MARV infection. METHODS: The activity of anti-MARV siRNAs was assessed using dual luciferase reporter assays followed by in vitro testing against live virus. Lead candidates were tested in lethal guinea pig models of 3 different MARV strains (Angola, Ci67, Ravn). RESULTS: Treatment resulted in 60%-100% survival of guinea pigs infected with MARV. Although treatment with siRNA targeting other MARV messenger RNA (mRNA) had a beneficial effect, targeting the MARV NP mRNA resulted in the highest survival rates. NP-718m siRNA in lipid nanoparticles provided 100% protection against MARV strains Angola and Ci67, and 60% against Ravn. A cocktail containing NP-718m and NP-143m provided 100% protection against MARV Ravn. CONCLUSIONS: These data show protective efficacy against the most pathogenic Angola strain of MARV. Further development of the lipid nanoparticle technology has the potential to yield effective treatments for MARV infection.


Subject(s)
Lipids/administration & dosage , Marburg Virus Disease/drug therapy , Marburg Virus Disease/prevention & control , Nanoparticles/administration & dosage , Nanoparticles/chemistry , RNA, Small Interfering/administration & dosage , Adaptor Proteins, Signal Transducing , Animals , Carrier Proteins/analysis , Cytokines/blood , Drug Carriers/chemistry , Female , Genes, Viral , Guinea Pigs , Lipids/chemistry , Liver/chemistry , Marburg Virus Disease/genetics , Marburg Virus Disease/metabolism , Marburgvirus/drug effects , Marburgvirus/genetics , Mice , Mice, Inbred ICR , RNA, Small Interfering/chemistry , RNA-Binding Proteins , Survival Analysis , Viral Load
13.
Mol Ther Nucleic Acids ; 2: e123, 2013 Sep 17.
Article in English | MEDLINE | ID: mdl-24045712

ABSTRACT

We previously identified short synthetic shRNAs (sshRNAs) that target a conserved hepatitis C virus (HCV) sequence within the internal ribosome entry site (IRES) of HCV and potently inhibit HCV IRES-linked gene expression. To assess in vivo liver delivery and activity, the HCV-directed sshRNA SG220 was formulated into lipid nanoparticles (LNP) and injected i.v. into mice whose livers supported stable HCV IRES-luciferase expression from a liver-specific promoter. After a single injection, RNase protection assays for the sshRNA and (3)H labeling of a lipid component of the nanoparticles showed efficient liver uptake of both components and long-lasting survival of a significant fraction of the sshRNA in the liver. In vivo imaging showed a dose-dependent inhibition of luciferase expression (>90% 1 day after injection of 2.5 mg/kg sshRNA) with t1/2 for recovery of about 3 weeks. These results demonstrate the ability of moderate levels of i.v.-injected, LNP-formulated sshRNAs to be taken up by liver hepatocytes at a level sufficient to substantially suppress gene expression. Suppression is rapid and durable, suggesting that sshRNAs may have promise as therapeutic agents for liver indications.Molecular Therapy-Nucleic Acids (2013) 2, e123; doi:10.1038/mtna.2013.50; published online 17 September 2013.

14.
Cancer Res ; 70(21): 8264-9, 2010 Nov 01.
Article in English | MEDLINE | ID: mdl-20959491

ABSTRACT

The development of targeted therapeutics for hepatocellular carcinoma (HCC) remains a major challenge. The ubiquitination modulator COP1 regulates p53 activity by ubiquitination and it is frequently overexpressed in human HCC. In this study, we tested the hypothesis that COP1 blockade by short interfering RNA (siRNA)-mediated inhibition could affect the course of HCC progression. The COP1 isoform COP1-1 was selected as the most effective target for siRNAs in terms of growth inhibition and apoptotic induction in several HCC cell lines. Growth inhibition occurred in HCC cells that retained wild-type p53 or expressed mutant p53 (Y220C or R249S), whereas p53-null Hep3B cells were resistant. Microarray expression analysis revealed that the antiproliferative effects of COP1 blockade were driven by a common subset of molecular alterations including a p53-associated functional network. In an orthotopic mouse xenograft model of HCC, systemic delivery of a modified COP1 siRNA by stable nucleic acid-lipid particles suppressed neoplastic growth in liver without unwanted immune responses. Our findings offer a first proof of principle that COP1 can be a promising target for systemic therapy of HCC.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/prevention & control , Liver Neoplasms/metabolism , Liver Neoplasms/prevention & control , Ubiquitin-Protein Ligases/metabolism , Ubiquitin/metabolism , Animals , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Blotting, Western , Carcinoma, Hepatocellular/genetics , Cell Cycle , Gene Expression Profiling , Humans , Liver Neoplasms/genetics , Male , Mice , Mice, SCID , Mutation/genetics , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , RNA, Small Interfering/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , Transplantation, Heterologous , Tumor Cells, Cultured , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Ubiquitin-Protein Ligases/antagonists & inhibitors , Ubiquitin-Protein Ligases/genetics , Ubiquitination
15.
Lancet ; 375(9729): 1896-905, 2010 May 29.
Article in English | MEDLINE | ID: mdl-20511019

ABSTRACT

BACKGROUND: We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) completely protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever. METHODS: A combination of modified siRNAs targeting the ZEBOV L polymerase (EK-1 mod), viral protein (VP) 24 (VP24-1160 mod), and VP35 (VP35-855 mod) were formulated in SNALPs. A group of macaques (n=3) was given these pooled anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques (n=4) was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV. FINDINGS: Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection. INTERPRETATION: This complete postexposure protection against ZEBOV in non-human primates provides a model for the treatment of ZEBOV-induced haemorrhagic fever. These data show the potential of RNA interference as an effective postexposure treatment strategy for people infected with Ebola virus, and suggest that this strategy might also be useful for treatment of other emerging viral infections. FUNDING: Defense Threat Reduction Agency.


Subject(s)
Ebolavirus/genetics , Hemorrhagic Fever, Ebola/prevention & control , RNA Interference , RNA, Small Interfering/therapeutic use , Animals , Chlorocebus aethiops , Ebolavirus/isolation & purification , Ebolavirus/physiology , Female , Hemorrhagic Fever, Ebola/virology , Infusions, Intravenous , Interferon-alpha/biosynthesis , Interleukin-6/biosynthesis , Macaca mulatta , Male , Mice , Mice, Inbred ICR , RNA, Small Interfering/adverse effects , RNA, Small Interfering/pharmacology , Vero Cells/virology , Viral Proteins/genetics , Viremia , Virus Replication
16.
Nat Biotechnol ; 28(2): 172-6, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20081866

ABSTRACT

We adopted a rational approach to design cationic lipids for use in formulations to deliver small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), a key lipid component of stable nucleic acid lipid particles (SNALP) as a benchmark, we used the proposed in vivo mechanism of action of ionizable cationic lipids to guide the design of DLinDMA-based lipids with superior delivery capacity. The best-performing lipid recovered after screening (DLin-KC2-DMA) was formulated and characterized in SNALP and demonstrated to have in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates. To our knowledge, this represents a substantial improvement over previous reports of in vivo endogenous hepatic gene silencing.


Subject(s)
Drug Carriers/chemistry , Drug Compounding/methods , Drug Design , Lipids/chemistry , RNA, Small Interfering/chemistry , Transfection/methods , Cations , RNA, Small Interfering/administration & dosage
17.
Oligonucleotides ; 19(2): 89-102, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19441890

ABSTRACT

Canonical small interfering RNA (siRNA) duplexes are potent activators of the mammalian innate immune system. The induction of innate immunity by siRNA is dependent on siRNA structure and sequence, method of delivery, and cell type. Synthetic siRNA in delivery vehicles that facilitate cellular uptake can induce high levels of inflammatory cytokines and interferons after systemic administration in mammals and in primary human blood cell cultures. This activation is predominantly mediated by immune cells, normally via a Toll-like receptor (TLR) pathway. The siRNA sequence dependency of these pathways varies with the type and location of the TLR involved. Alternatively nonimmune cell activation may also occur, typically resulting from siRNA interaction with cytoplasmic RNA sensors such as RIG1. As immune activation by siRNA-based drugs represents an undesirable side effect due to the considerable toxicities associated with excessive cytokine release in humans, understanding and abrogating this activity will be a critical component in the development of safe and effective therapeutics. This review describes the intracellular mechanisms of innate immune activation by siRNA, the design of appropriate sequences and chemical modification approaches, and suitable experimental methods for studying their effects, with a view toward reducing siRNA-mediated off-target effects.


Subject(s)
Antigen-Presenting Cells/immunology , Cytokines/immunology , Immunity, Innate/immunology , RNA, Small Interfering/immunology , Animals , Antigen-Presenting Cells/metabolism , Cytokines/metabolism , DEAD-box RNA Helicases/immunology , DEAD-box RNA Helicases/metabolism , Humans , Interferons/immunology , Interferons/metabolism , Lymphocyte Activation/immunology , RNA, Small Interfering/metabolism , Toll-Like Receptor 3/immunology , Toll-Like Receptor 3/metabolism , Toll-Like Receptor 7/immunology , Toll-Like Receptor 7/metabolism , Toll-Like Receptor 8/immunology , Toll-Like Receptor 8/metabolism
18.
J Clin Invest ; 119(3): 661-73, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19229107

ABSTRACT

siRNAs that specifically silence the expression of cancer-related genes offer a therapeutic approach in oncology. However, it remains critical to determine the true mechanism of their therapeutic effects. Here, we describe the preclinical development of chemically modified siRNA targeting the essential cell-cycle proteins polo-like kinase 1 (PLK1) and kinesin spindle protein (KSP) in mice. siRNA formulated in stable nucleic acid lipid particles (SNALP) displayed potent antitumor efficacy in both hepatic and subcutaneous tumor models. This was correlated with target gene silencing following a single intravenous administration that was sufficient to cause extensive mitotic disruption and tumor cell apoptosis. Our siRNA formulations induced no measurable immune response, minimizing the potential for nonspecific effects. Additionally, RNAi-specific mRNA cleavage products were found in tumor cells, and their presence correlated with the duration of target mRNA silencing. Histological biomarkers confirmed that RNAi-mediated gene silencing effectively inhibited the target's biological activity. This report supports an RNAi-mediated mechanism of action for siRNA antitumor effects, suggesting a new methodology for targeting other key genes in cancer development with siRNA-based therapeutics.


Subject(s)
Genetic Therapy , Neoplasms/genetics , Neoplasms/therapy , RNA Interference , RNA, Small Interfering/genetics , Animals , Cell Cycle Proteins/genetics , Disease Models, Animal , Gene Duplication , Mice , Neoplasms, Experimental/genetics , Neoplasms, Experimental/pathology , Polymerase Chain Reaction , Protein Serine-Threonine Kinases/deficiency , Protein Serine-Threonine Kinases/genetics , Proto-Oncogene Proteins/deficiency , Proto-Oncogene Proteins/genetics , RNA, Messenger/genetics , RNA, Neoplasm/genetics , Polo-Like Kinase 1
19.
Hum Gene Ther ; 19(10): 991-9, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18713023

ABSTRACT

Activation of innate immunity has direct effects in modulating viral replication, tumor growth, angiogenesis, and inflammatory and other immunological processes. It is now established that unmodified siRNA can activate this innate immune response and therefore there is real potential for siRNA to elicit nonspecific therapeutic effects in a wide range of disease models. Here we demonstrate that in a murine model of influenza infection, the antiviral activity of siRNA is due primarily to immune stimulation elicited by the active siRNA duplexes and is not the result of therapeutic RNA interference (RNAi) as previously reported. We show that the misinterpretation stems from the use of a particular control green fluorescent protein (GFP) siRNA that we identify as having unusually low immunostimulatory activity compared with the active anti-influenza siRNA. Curiously, this GFP siRNA has served as a negative control for a surprising number of groups reporting therapeutic effects of siRNA. The inert immunologic profile of the GFP sequence was unique among a broad panel of published siRNAs, all of which could elicit significant interferon induction from primary immune cells. This panel included eight active siRNAs against viral, angiogenic, and oncologic targets, the reported therapeutic efficacy of which was based on comparison with the nonimmunostimulatory GFP siRNA. These results emphasize the need for researchers to anticipate, monitor, and adequately control for siRNA-mediated immune stimulation and calls into question the interpretation of numerous published reports of therapeutic RNAi in vivo. The use of chemically modified siRNA with minimal immunostimulatory capacity will help to delineate more accurately the mechanism of action underlying such studies.


Subject(s)
Influenza A virus/immunology , Influenza, Human/immunology , RNA, Small Interfering/immunology , Animals , Cell Line , Disease Models, Animal , Dogs , Genetic Therapy , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/immunology , Humans , Influenza A virus/genetics , Influenza, Human/genetics , Influenza, Human/therapy , Mice , Mice, Inbred BALB C , RNA, Small Interfering/genetics
SELECTION OF CITATIONS
SEARCH DETAIL